Journal Guide

Rheumatology is an international peer review journal publishing the highest quality scientific and clinical papers. The scope of Rheumatology includes a range of rheumatological conditions, musculoskeletal medicine, surgery and translational research. Rheumatology aims to provide very rapid publication of all papers both online and in hard copy.Rheumatology publishes original articles, concise reports, reviews, editorials, guidelines, case reports, clinical vignettes, letters and matters arising from published material.

The international journal Synergy is dedicated to the understanding, development and application of the principle of "synergy" at the molecular, cellular and organismic levels and its application in the prevention and treatment of disease.Multimodal treatments or multitarget approaches are increasingly applied to treat complex diseases in different disciplines of medicine – mainly based on empirical knowledge. There is a need to elucidate and define further the combinatory actions in the context of the theoretical basis, experimental design and quantification of synergy at different dose and effect levels, including optimal combination ratios or sequences and the prevention of potential adverse events.The journal Synergy aims to serve as an international platform for the dissemination, exchange and discourse of innovative research on the systematic development of combination therapies based on synergistic effects and the quantification and quantitative simulation of synergistic and/or antagonistic modes of action. Preclinical and clinical research results are invited from the fields of medicine, molecular and cellular biology, toxicology, pharmacology, pharmacy, and bioinformatics.Synergy publishes research on combinations of single and multicomponent drugs of synthetic or of natural origin. Its scope includes "Omic" approaches, which contribute to the understanding of complex disease traits and bring them into the context of system biology.Synergy welcomes relevant contributions in the forms of original research papers, reviews, rapid communications, perspectives and letters to the editor. Commentaries are by invitation only.

Despite the major efforts made in oncology over the past ten years, only relatively modest improvements have been made in the conventional treatment of cancer. Recently, a better understanding of molecular pathways has provided pathologists with clues to the parthenogenesis of the disease and multiple targets for new strategies. New treatments, monoclonal antibodies or small molecules, have emerged targeting these pathways and inhibiting tumor growth and progression. These 'mabs' and 'nibs' constitute a new language with its own grammar that oncologists have to learn. Significant work remains in controlling theses processes and understanding these new compounds. This journal aims to be a pragmatic tool for all physicians committed to the field, focusing on insight into the basic science of cellular functions, critical reviews of clinical data. The Société française d'angiogenèse is affiliated to the journal.